Scarica l'app Stockscreener
0.758
4.05%
-0.032
Dopo l'orario di chiusura:
.75
-0.008
-1.06%
Precedente Chiudi:
$0.79
Aprire:
$0.8053
Volume 24 ore:
257.61K
Relative Volume:
0.46
Capitalizzazione di mercato:
$39.29M
Reddito:
-
Utile/perdita netta:
$-81.22M
Rapporto P/E:
-0.2561
EPS:
-2.96
Flusso di cassa netto:
$-74.41M
1 W Prestazione:
-9.58%
1M Prestazione:
-1.01%
6M Prestazione:
+0.01%
1 anno Prestazione:
-5.25%
Intervallo 1D:
$0.7511
$0.8053
Intervallo di 1 settimana:
$0.742
$0.86
Portata 52W:
$0.615
$1.70
Xilio Therapeutics Inc Stock (XLO) Company Profile
Nome
Xilio Therapeutics Inc
Settore
Industria
Telefono
617-833-1027
Indirizzo
828 WINTER STREET, WALTHAM
Confronta XLO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.758 | 39.34M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Iniziato | Leerink Partners | Outperform |
| 2022-12-21 | Iniziato | Chardan Capital Markets | Buy |
| 2022-01-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-16 | Iniziato | Cowen | Outperform |
| 2021-11-16 | Iniziato | Guggenheim | Buy |
| 2021-11-16 | Iniziato | Morgan Stanley | Overweight |
| 2021-11-16 | Iniziato | Raymond James | Outperform |
Mostra tutto
Xilio Therapeutics Inc Borsa (XLO) Ultime notizie
How Xilio Therapeutics Inc. stock compares to market leaders2025 Market Trends & Verified Entry Point Signals - newser.com
Why analysts remain bullish on Xilio Therapeutics Inc. stockGlobal Markets & AI Forecast for Swing Trade Picks - newser.com
Volatility clustering patterns for Xilio Therapeutics Inc.2025 Market Overview & Smart Allocation Stock Reports - newser.com
What the charts say about Xilio Therapeutics Inc. todayJuly 2025 Price Swings & Accurate Intraday Trading Signals - newser.com
Using data models to predict Xilio Therapeutics Inc. stock movementQuarterly Risk Review & Low Risk High Reward Ideas - newser.com
How Xilio Therapeutics Inc. stock responds to policy changesQuarterly Performance Summary & Fast Entry and Exit Trade Plans - newser.com
Can Xilio Therapeutics Inc. stock deliver sustainable ROEJuly 2025 Trade Ideas & Safe Capital Growth Plans - newser.com
Using AI based signals to follow Xilio Therapeutics Inc.Trade Ideas & Daily Profit Maximizing Tips - newser.com
Will Xilio Therapeutics Inc. stock remain a Wall Street favorite2025 Buyback Activity & Weekly Chart Analysis and Guides - newser.com
Using flow based indicators on Xilio Therapeutics Inc.July 2025 Spike Watch & Daily Market Momentum Tracking - newser.com
Xilio Therapeutics’ (XLO) Sell (E+) Rating Reiterated at Weiss Ratings - Defense World
Is Xilio Therapeutics Inc. reversing from oversold territory2025 Geopolitical Influence & Community Consensus Trade Signals - newser.com
Evaluating Xilio Therapeutics Inc. with trendline analysisJuly 2025 Movers & High Yield Equity Trading Tips - newser.com
Using R and stats models for Xilio Therapeutics Inc. forecastingJuly 2025 Rallies & Intraday High Probability Alerts - newser.com
Xilio Therapeutics Transfers Listing to Nasdaq Capital Market - The Globe and Mail
Xilio Therapeutics Announces Upcoming Presentations at the - GlobeNewswire
Xilio Therapeutics announces upcoming presentations at the Society for Immunotherapy of Cancer - MarketScreener
GlobeNewswire by Notified - The Manila Times
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting - The Manila Times
Xilio Therapeutics Announces Multiple Poster Presentations at SITC 40th Annual Meeting Including Clinical Data for Vilastobart and XTX301 - Quiver Quantitative
3 Posters at SITC Nov 6-9, 2025: Xilio Presents vilastobart, XTX301 & Masked T Cell Engagers - Stock Titan
Xilio Therapeutics to transfer listing to Nasdaq Capital Market on Monday - Investing.com
Xilio Therapeutics transfers listing of co's common stock to Nasdaq Capital Market - MarketScreener
Detecting support and resistance levels for Xilio Therapeutics Inc.Weekly Profit Report & Expert Approved Momentum Trade Ideas - newser.com
Has Xilio Therapeutics Inc. found a price floorTrade Exit Summary & Reliable Intraday Trade Alerts - newser.com
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
26,000-Share Grant: Xilio Therapeutics Grants Options at $0.8326 Exercise Price - Stock Titan
Xilio Therapeutics Inc Stock Analysis and ForecastVolatility Index Analysis & AI Alerts You Can Actually Trust - earlytimes.in
Xilio Therapeutics Inc Azioni (XLO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Xilio Therapeutics Inc Azioni (XLO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shannon James Samuel | Director |
Jun 17 '25 |
Buy |
0.69 |
25,000 |
17,215 |
70,000 |
| Russo Rene | PRESIDENT AND CEO |
Jun 16 '25 |
Buy |
0.68 |
36,289 |
24,680 |
281,172 |
| Frankenfield Christopher James | Chief Financial Officer |
Jan 02 '25 |
Sale |
0.98 |
6,954 |
6,841 |
12,421 |
| Brennan Kevin M. | SVP, FINANCE AND ACCOUNTING |
Jan 02 '25 |
Sale |
0.98 |
1,803 |
1,774 |
3,197 |
| GILEAD SCIENCES, INC. | 10% Owner |
Dec 18 '24 |
Buy |
1.04 |
1,759,978 |
1,830,377 |
9,105,451 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):